Haemophilia A: Encouraging new data on treatment in newborns

There is still good news about the drug emicizumab for the treatment of haemophilia A. Following the results of the HAVEN 6 study presented in July, which also showed its efficacy in patients with mild and moderate haemophilia A, the phase III HAVEN 7 study confirms the efficacy and safety of emicizumab in infants with severe haemophilia A, without factor VIII inhibitors.